Immunotherapy approaches in cancer treatment

Current Pharmaceutical Biotechnology

Volumn 16, Issue 9, 2015, Pages 771-781

  Klener, Pavel ^a,a,b,d   Otáhal, Pavel ^a,c   Lateckova, Lucie ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF MATHEMATICS   (Czech Republic)

^d INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Adoptive T cell therapy; Cancer immunotherapy; Cancer vaccines; Chimeric antigen receptor (CAR); Cytokines; Monoclonal antibodies

Indexed keywords

ABAGOVOMAB; ALPHA INTERFERON; BELATACEPT; BLINATUMOMAB; BROLIZUMAB; CANCER VACCINE; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DNA VACCINE; GROWTH FACTOR; IMMUNOCYTOKINE; INTERFERON; INTERLEUKIN DERIVATIVE; IPILIMUMAB; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; OBINUTUZUMAB; PEMBROLIZUMAB; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 21; RECOMBINANT INTERLEUKIN 24; RITUXIMAB; ROMIPLOSTIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; XATUMAXOMAB; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; IMMUNITY; IMMUNOSURVEILLANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84938599283     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201016666150619114554     Document Type: Article

References (84)

1. [1] Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. Cell, 2000, 100, 57-70.
2. [2] Küppers, R. New insights in the biology of Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program, 2012, 2012, 328-334.
3. [3] Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144, 646-674.
4. [4] Cavallo, F.; De Giovanni, C.; Nanni, P.; Forni, G.; Lollini, P.L. 2011. The immune hallmarks of cancer. Cell, 2011, 60, 319-326.
5. [5] Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 2011, 331, 1565-1570.
6. [6] Matsushita, H.; Vesely, M.D.; Koboldt, D.C.; Rickert, C.G.; Uppaluri, R.; Magrini, V.J.; Arthur, C.D.; White, J.M.; Chen, Y.S.; Shea, L. K.; Hundal, J.; Wendl, M.C.; Demeter, R.; Wylie, T.; Allison, J.P.; Smyth, M.J.; Old, L.J.; Mardis, E.R.; Schreiber, R.D. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature, 2012, 482, 400-404.
7. [7] DuPage, M.; Mazumdar, C.; Schmidt, L.M.; Cheung, A.F.; Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 2012, 482, 405-409.
8. [8] Wu, Y.L.; Ding, Y.P.; Tanaka, Y.; Shen, L.W.; Wei, C.H.; Minato, N.; Zhang, W. γδ T cells and their potential for immunotherapy. Int. J. Biol. Sci., 2014, 10, 119-135.
9. [9] Latha, T.S.; Reddy, M.C.; Durbaka, P.V.R.; Rachamallu, A.; Pallu, R.; Lomada, D. γδ T Cell-Mediated Immune Responses in Disease and Therapy. Front. Immunol., 2014, 5, 571.
10. [10] Parmar, S.; Ritchie, D.S. Allogeneic transplantation as anticancer immunotherapy. Curr. Opin. Immunol., 2014, 27, 38-45.
11. [11] Lee, S.; Margolin, K. Cytokines in cancer immunotherapy. Cancers (Basel)., 2011, 3, 3856-3893.
12. [12] Anestakis, D.; Petanidis, S.; Kalyvas, S.; Nday, C.M.; Tsave, O.; Kioseoglou, E.; Salifoglou, A. Mechanisms and Αpplications of Ιnterleukins in Cancer Immunotherapy. Int. J. Mol. Sci., 2015, 16, 1691-1710.
13. [13] Bekisz, J.; Baron, S.; Balinsky, C.; Morrow, A.; Zoon, K.C. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel)., 2010, 3, 994-1015.
14. [14] Aricò, E.; Belardelli, F. Interferon-α as antiviral and antitumor vaccine adjuvants: mechanisms of action and response signature. J. Interferon Cytokine Res., 2012, 32, 235-247.
15. [15] Quesada, J.R.; Reuben, J.; Manning J.T.; Hersh E.M.; Gutterman, J.U. Alpha interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med., 1984, 310(1), 15-8.
16. [16] Talpaz, M.; Kantarjian, H.M.; McCredie, K.B.; Keating, M.J.; Trujillo, J.; Gutterman, J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood, 1987, 69, 1280-1288.
17. [17] Kirkwood, J.M.; Strawderman, M.H.; Ernstoff, M.S.; Smith, T.J.; Borden, E.C.; Blum, R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol., 1996, 14, 7-17.
18. [18] Krown, S.E.; Real, F.X.; Cunningham-Rundles, S.; Myskowski P. L.; Koziner, B.; Fein, S.; Mittelman, A.; Oettgen, H.F.; Safai, B. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. N Engl. J Med., 1983, 308, 1071-1076.
19. [19] Rosenberg, S.A. IL-2: the first effective immunotherapy for human cancer. J. Immunol., 2014, 192, 5451-5458.
20. [20] Kradin, R.L.; Kurnick, J.T.; Lazarus, D.S.; Preffer, F.I.; Dubinett, S.M.; Pinto, C.E.; Gifford, J.; Davidson, E.; Grove, B.; Callahan, R.J. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet, 1989, 1, 577-580.
21. [21] Kontermann, R.E. Antibody-cytokine fusion proteins. Arch. Biochem. Biophys. 2012, 526, 194-205.
22. [22] Kaminetzky, D.; Hymes, K.B. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics, 2008, 2, 717-724.
23. [23] Yang, A.S. Development of Romiplostim: A Novel Engineered Peptibody. Semin. Hematol. 2015, 52, 12-15.
24. [24] Zhang, X.; Zhang, L.; Xu, W.; Qian, H.; Ye, S.; Zhu, W.; Cao, H.; Yan, Y.; Li, W.; Wang, M.; Wang, W.; Zhang, R. Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr Cancer Drug Targets, 2013, 13, 92-102.
25. [25] Wajant, H.; Gerspach, J.; Pfizenmaier, K. Engineering death receptor ligands for cancer therapy. Cancer Lett., 2013, 332, 163-174.
26. [26] De Bruyn, M.; Bremer, E.; Helfrich, W. Antibody-based fusion proteins to target death receptors in cancer. Cancer Lett., 2013, 332, 175-183.
27. [27] Micheau, O.; Shirley, S.; Dufour, F. Death receptors as targets in cancer. Br. J. Pharmacol., 2013, 169, 1723-1744.
28. [28] Monaco, C.; Nanchahal, J.; Taylor, P.; Feldmann, M. Anti-TNF Therapy: Past, Present and Future. Int. Immunol., 2014, 27, 55-62.
29. [29] Kaufman, H.L.; Ruby, C.E.; Hughes, T.; Slingluff, C.L. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J. Immunother. Cancer, 2014, 2, 11.
30. [30] Zhou, L.; Xu, N.; Sun, Y.; Liu, X.M. Targeted biopharmaceuticals for cancer treatment. Cancer Lett., 2014, 352, 145-151.
31. [31] Lim, S.H.; Beers, S.A.; French, R.R.; Johnson, P. W. M.; Glennie, M.J.; Cragg, M.S. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica, 2010, 95, 135-143.
32. [32] Reichert, J.M. Antibodies to watch in 2015. MAbs, 2015, 7, 1-8.
33. [33] Postow, M.A.; Callahan, M.K.; Wolchok, J.D. Immune Checkpoint Blockade in Cancer Therapy. J. Clin. Oncol., 2015.
34. [34] Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; Akerley, W.; van den Eertwegh, A.J.M.; Lutzky, J.; Lorigan, P.; Vaubel, J.M.; Linette, G.P.; Hogg, D.; Ottensmeier, C.H.; Lebbé, C.; Peschel, C.; Quirt, I.; Clark, J.I.; Wolchok, J.D.; Weber, J.S.; Tian, J.; Yellin, M.J.; Nichol, G.M.; Hoos, A.; Urba, W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 2010, 363, 711-723.
35. [35] Ott, P.A.; Hodi, F.S.; Robert, C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res., 2013, 19, 5300-5309.
36. [36] Panowksi, S.; Bhakta, S.; Raab, H.; Polakis, P.; Junutula, J.R. Sitespecific antibody drug conjugates for cancer therapy. MAbs, 6, 34-45.
37. [37] Firer, M.A.; Gellerman, G. Targeted drug delivery for cancer therapy: the other side of antibodies. J. Hematol. Oncol., 2012, 5, 70.
38. [38] Herter, S.; Birk, M.C.; Klein, C.; Gerdes, C.; Umana, P.; Bacac, M. Glycoengineering of therapeutic antibodies enhances monocyte/ macrophage-mediated phagocytosis and cytotoxicity. J. Immunol., 2014, 192, 2252-2260.
39. [39] Yoshie, O.; Matsushima, K. CCR4 and its ligands: from bench to bedside. Int. Immunol., 2015, 27, 11-20.
40. [40] Goede, V.; Fischer, K.; Busch, R.; Engelke, A.; Eichhorst, B.; Wendtner, C.M.; Chagorova, T.; de la Serna, J.; Dilhuydy, M.S.; Illmer, T.; Opat, S.; Owen, C.J.; Samoylova, O.; Kreuzer, K.A.; Stilgenbauer, S.; Döhner, H.; Langerak, A.W.; Ritgen, M.; Kneba, M.; Asikanius, E.; Humphrey, K.; Wenger, M.; Hallek, M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med., 2014, 370, 1101-1110.
41. [41] Seimetz, D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J. Cancer, 2011, 2, 309-316.
42. [42] Maher, J.; Adami, A.A. Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies? Cancer Res., 2013, 73, 5613-5617.
43. [43] Grisham, R.N.; Berek, J.; Pfisterer, J.; Sabbatini, P. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy, 2011, 3, 153-162.
44. [44] Hernández, A.M.; Vázquez, A.M. Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer. Expert Rev., Vaccines, 2015, 14, 9-20.
45. [45] Fournier, P.; Schirrmacher, V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs, 2013, 27, 35-53.
46. [46] Huehls, A.M.; Coupet, T.A.; Sentman, C.L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol., 2014.
47. [47] Baeuerle, P.A.; Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res., 2009, 69, 4941-4944.
48. [48] Czajkowsky, D.M.; Hu, J.; Shao, Z.; Pleass, R.J. Fc-fusion proteins: new developments and future perspectives. EMBO Mol. Med., 2012, 4, 1015-1028.
49. [49] Epstein, W.V. Treatment of rheumatoid arthritis with a tumor necrosis factor receptor-Fc fusion protein. N. Engl. J. Med., 1997, 337, 1559-1560; author reply 1560-1561.
50. [50] El-Charabaty, E.; Geara, A.S.; Ting, C.; El-Sayegh, S.; Azzi, J. Belatacept: A new era of immunosuppression? Expert Rev. Clin. Immunol., 2012, 8, 527-536.
51. [51] O’Brien, M.A.; Power, D.G.; Clover, A.J.P.; Bird, B.; Soden, D.M.; Forde, P.F. Local tumour ablative therapies: opportunities for maximising immune engagement and activation. Biochim. Biophys. Acta, 2014, 1846, 510-523.
52. [52] Mariño, G.; Niso-Santano, M.; Baehrecke, E.H.; Kroemer, G. Selfconsumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol., 2014, 15, 81-94.
53. [53] Inoue, H.; Tani, K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ., 2014, 21, 39-49.
54. [54] Laoui, D.; Van Overmeire, E.; De Baetselier, P.; Van Ginderachter, J.A.; Raes, G. Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front. Immunol., 2014, 5, 489.
55. [55] Butt, A.Q.; Mills, K.H.G. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2014, 33, 4623-4631.
56. [56] Palucka, K.; Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. Immunity, 2013, 39, 38-48.
57. [57] Graff, J. N.; Chamberlain, E. D. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evid., 2015, 10, 1-10.
58. [58] Lichty, B.D.; Breitbach, C.J.; Stojdl, D.F.; Bell, J.C. Going viral with cancer immunotherapy. Nat. Rev. Cancer, 2014, 14, 559-567.
59. [59] Bauzon, M.; Hermiston, T. Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy. Front. Immunol., 2014, 5, 74.
60. [60] Ragonnaud, E.; Holst, P. The rationale of vectored gene-fusion vaccines against cancer: Evolving strategies and latest evidence. Ther. Adv. Vaccines, 2013, 1, 33-47.
61. [61] Singh, R.; Lillard, J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86, 215-23.
62. [62] Zhaoa, L.; Setha, A.; Wibowoa, N.; Zhaoa, C.X.; Mitterb, N.; Yua, C.; Middelberg, A.P.J. Nanoparticle vaccines. Vaccine, 2014, 32(3), 327-37.
63. [63] Conniot, J.; Silva, J.M.; Fernandes, J.G.; Silva, L.C.; Gaspar, R.; Brocchini, S.; Florindo, H.F.; Barata, T.S. Cancer immunotherapy: Nanodelivery approaches for immune cell targeting and tracking. Front Chem., 2014, 26,105.
64. [64] Sahdev, P.; Ochyl, L.J.; Moon, J.J. Biomaterials for nanoparticle vaccine delivery systems. Pharm. Res., 2014, 31, 2563-82.
65. [65] Kalos, M.; June, C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity, 2013, 39, 49-60.
66. [66] Shi, H.; Liu, L.; Wang, Z. Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett., 2013, 328, 191-197.
67. [67] Robbins, P.F.; Lu, Y.C.; El-Gamil, M.; Li, Y.F.; Gross, C.; Gartner, J.; Lin, J.C.; Teer, J.K.; Cliften, P.; Tycksen, E.; Samuels, Y.; Rosenberg, S.A. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med., 2013, 19, 747-752.
68. [68] Robbins, P.F.; Kassim, S.H.; Tran, T.L.N.; Crystal, J.S.; Morgan, R.A.; Feldman, S.A.; Yang, J.C.; Dudly, M.E.; Wunderlich, J.R.; Sherry, R.M.; Kammula, U.S.; Hughes, M.S.; Restifo, N.P.; Raffeld, M.; Lee, C.C. R.; Li, Y.F.; El-Gamil, M.; Rosenberg, S.A.A pilot trial using lymphocytes genetically engineered with an NYESO- 1-reactive T cell receptor: Long term follow up and correlates with response. Clin. Cancer Res., 2014.
69. [69] Kunert, A.; Straetemans, T.; Govers, C.; Lamers, C.; Mathijssen, R.; Sleijfer, S.; Debets, R. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, t cell fitness, and sensitization of tumor milieu. Front. Immunol., 2013, 4, 363.
70. [70] Oren, R.; Hod-Marco, M.; Haus-Cohen, M.; Thomas, S.; Blat, D.; Duvshani, N.; Denkberg, G.; Elbaz, Y.; Benchetrit, F.; Eshhar, Z.; Stauss, H.; Reiter, Y. Functional comparison of engineered T Cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J. Immunol., 2014, 193, 5733-5743.
71. [71] Maher, J. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol., 2012, 2012, 278093.
72. [72] Chmielewski, M.; Hombach, A.A.; Abken, H. Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev., 2014, 257, 83-90.
73. [73] Vesely, M.D.; Schreiber, R.D. Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy. Ann. NY Acad. Sci., 2013, 1284, 1-5.
74. [74] Maus, M.V; Grupp, S.A.; Porter, D.L.; June, C.H. Antibodymodified T cells: CARs take the front seat for hematologic malignancies. Blood, 2014, 123, 2625-2635.
75. [75] Maude, S.L.; Frey, N.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Bunin, N.J.; Chew, A.; Gonzalez, V.E.; Zheng, Z.; Lacey, S.F.; Mahnke, Y.D.; Melenhorst, J.; Rheingold, S.R.; Shen, A.; Teachey, D.T.; Levine, B.L.; June, C.H.; Porter, D.L.; Grupp, S.A. Chimeric antigen receptor t cells for sustained remissions in leukemia. N. Engl. J. Med., 2014, 371, 1507-1517.
76. [76] Grupp, S.A.; Kalos, M.; Barrett, D.; Aplenc, R.; Porter, D.L.; Rheingold, S.R.; Teachey, D.T.; Chew, A.; Hauck, B.; Wright, J. F.; Milone, M.C.; Levine, B.L.; June, C.H. Chimeric antigen receptor- modified T cells for acute lymphoid leukemia. N. Engl. J. Med., 2013, 368, 1509-1518.
77. [77] Maude, S.L.; Barrett, D.; Teachey, D.T.; Grupp, S.A. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J., 20, 119-122.
78. [78] Stauss, H.J.; Morris, E.C. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther., 2013, 20, 1029-1032.
79. [79] Lamers, C.H.; Sleijfer, S.; van Steenbergen, S.; van Elzakker, P.; van Krimpen, B.; Groot, C.; Vulto, A.; den Bakker, M.; Oosterwijk, E.; Debets, R.; Gratama, J.W. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity. Mol. Ther., 2013, 21, 904-912.
80. [80] Morgan, R.A.; Yang, J.C.; Kitano, M.; Dudley, M.E.; Laurencot, C.M.; Rosenberg, S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther., 2010, 18, 843-851.
81. [81] Chouaib, S.; Pittari, G.; Nanbakhsh, A.; El Ayoubi, H.; Amsellem, S.; Bourhis, J.H.; Spanholtz, J. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front. Immunol., 2014, 5, 95.
82. [82] Bachanova, V.; Miller, J.S. NK cells in therapy of cancer. Crit. Rev. Oncog., 2014, 19, 133-141.
83. [83] Moretta, L.; Pietra, G.; Montaldo, E.; Vacca, P.; Pende, D.; Falco, M.; Del Zotto, G.; Locatelli, F.; Moretta, A.; Mingari, M.C. Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front. Immunol., 2014, 5, 87.
84. [84] Eguizabal, C.; Zenarruzabeitia, O.; Monge, J.; Santos, S.; Vesga, M.A.; Maruri, N.; Arrieta, A.; Riñón, M.; Tamayo-Orbegozo, E.; Amo, L.; Larrucea, S.; Borrego, F. Natural killer cells for cancer immunotherapy: Pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. Front. Immunol., 2014, 5, 439.